Condition: Prostatic Neoplasms · Sponsor: Janssen Research & Development, LLC
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of the combination of JNJ-87189401 and JNJ-78278343 is, with or without apalutamide. Part 3 of this study evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with standard of care (SOC) lutetium Lu-177 vipivotide tetraxetan. Part 4 of this study further evaluates the safety of the triplet combination of JNJ-87189401 and JNJ-78278343 with JNJ-101556143 in participants with advanced prostate cancer.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| University of Colorado Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Emory University Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| University Of Minnesota | Minneapolis, Minnesota, United States | Recruiting |
| START New Jersey | East Brunswick, New Jersey, United States | Recruiting |
| Herbert Irving Comprehensive Cancer Center Columbia University Medical Center | New York, New York, United States | Recruiting |
| Oregon Health And Science University | Portland, Oregon, United States | Recruiting |
| Sidney Kimmel Cancer Center - Jefferson Health | Philadelphia, Pennsylvania, United States | Recruiting |
| Tennessee Oncology | Nashville, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| South Texas Accelerated Research Therapeutics, LLC (START) | San Antonio, Texas, United States | Recruiting |
| Swedish Medical Center | Seattle, Washington, United States | Recruiting |
| Peter MacCallum Cancer Centre | Melbourne, Australia | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06095089